Purification process development for HER1 extracellular domain as a potential therapeutic vaccine

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Oct 1;877(27):3105-10. doi: 10.1016/j.jchromb.2009.07.041. Epub 2009 Aug 11.

Abstract

HER1 is a tumor associated antigen emerging as an attractive target for cancer therapy. In the present study we demonstrated for first time that HER1 extracellular domain can be purified by a downstream process at pilot scale based on immunoaffinity chromatography from bioreactor supernatant of HEK 293 transfectomes. Filtered supernatant was applied to CNBr-activated Sepharose CL-4B with monoclonal antibody anti-human EGF immobilized, followed by three additional chromatographic polishing steps. HER1 extracellular domain was obtained with high purity (>95%), low DNA content, and biological activity.

MeSH terms

  • Antibodies, Monoclonal / chemistry
  • Antibodies, Monoclonal / immunology
  • Cancer Vaccines / chemistry
  • Cancer Vaccines / immunology
  • Cell Line
  • Chromatography, Affinity / methods*
  • Chromatography, Gel
  • Chromatography, Ion Exchange
  • ErbB Receptors / chemistry
  • ErbB Receptors / genetics
  • ErbB Receptors / immunology
  • ErbB Receptors / isolation & purification*
  • Flow Cytometry
  • Humans
  • Protein Structure, Tertiary
  • Tandem Mass Spectrometry
  • Transfection

Substances

  • Antibodies, Monoclonal
  • Cancer Vaccines
  • EGFR protein, human
  • ErbB Receptors